Title
Risk of COVID-19 in Dermatologic Patients on Long-term Immunomodulatory Therapy
UMMS Affiliation
School of Medicine
Publication Date
2020-07-01
Document Type
Article
Disciplines
Dermatology | Immunotherapy | Infectious Disease | Skin and Connective Tissue Diseases | Virus Diseases
Abstract
As the COVID-19 pandemic has rapidly spread around the globe, concern has been raised regarding susceptibility of patients on immunomodulatory therapies to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection. While general guidance has been put forth, data regarding infection rate and outcomes in immunosuppressed patients is still rare.1 Recent articles, including the work by Gisondi, et al, suggest that outcomes of patients on systemic immunomodulatory therapies infected with SARS-CoV-2 are similar to the general population.2 These findings may relate to the aberrant cytokine and inflammatory responses in severe COVID-19, which may be treated or partially blunted by cytokine-targeted therapy.3 Given the substantial outbreak of COVID-19 in our community, we tested whether, in addition to similar outcomes, patients on systemic immunomodulatory therapy had similar infection rates compared to the general population.
Keywords
COVID-19, Dupilumab, IL-17 inhibitor, IL-23 inhibitor, IL12/23 inhibitor, Jak inhibitor, TNF alpha inhibitor, adalimumab, apremilast, biologics, coronavirus, cyclosporine, etanercept, guselkumab, immunosuppression, infliximab, ixekizumab, methotrexate, mycophenolate mofetil, risankizumab, secukinumab, tofacitinib, ustekinumab
DOI of Published Version
10.1016/j.jaad.2020.06.999
Source
Holcomb ZE, Santillan MR, Morss-Walton PC, Salian P, Her MJ, Giannotti NM, Kimball AB, Porter ML. Risk of COVID-19 in Dermatologic Patients on Long-term Immunomodulatory Therapy. J Am Acad Dermatol. 2020 Jul 1:S0190-9622(20)32099-5. doi: 10.1016/j.jaad.2020.06.999. Epub ahead of print. PMID: 32622141; PMCID: PMC7329682. Link to article on publisher's site
Journal/Book/Conference Title
Journal of the American Academy of Dermatology
Related Resources
PubMed ID
32622141
Repository Citation
Holcomb ZE, Santillan MR, Morss-Walton PC, Salian P, Her MJ, Giannotti NM, Kimball AB, Porter ML. (2020). Risk of COVID-19 in Dermatologic Patients on Long-term Immunomodulatory Therapy. COVID-19 Publications by UMMS Authors. https://doi.org/10.1016/j.jaad.2020.06.999. Retrieved from https://escholarship.umassmed.edu/covid19/64